MHC Ib-mediated pancreatic islet antigen-specific immunosuppression as novel therapy for type 1 diabetes

By using recombinant polypeptides, combining peptide antigens and non-classical MHC class Ib molecules, the narrow problem of immune response inhibition in the treatment of type 1 diabetes is solved, selective tolerance induction of specific antigens is achieved, and clinical results of patients are improved. And helps regeneration of pancreatic tissue.

CN118922202APending Publication Date: 2024-11-08JULIUS MAXIMILIANS UNIV WURZBURG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029747.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-24
Filing Date
2023-03-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing treatment methods for type 1 diabetes (T1D) have a narrow therapeutic window for systemic immunosuppression, which is difficult to effectively inhibit the response of CD8 T cells and autoantibodies, resulting in limited therapeutic effects and complex insulin management, making it difficult to meet patients' medical needs.

Method used

Recombinant polypeptides, including peptide antigens, non-classical human MHC class Ib molecules (such as HLA-G) and β2-microglobulins, are used to form soluble peptides through covalent ligation, which are used to inhibit immune responses against specific antigens and induce selective tolerance. Receptive while maintaining a protective immune response to pathogens.

Benefits of technology

Effectively inhibit the immune response against proinsulin, glutamate decarboxylase 65, islet amyloid peptide and zinc transporter 8, prevent the formation of autoantibodies, improve the clinical outcomes of type 1 diabetes patients, and use in combination with stem cell therapy can help promote Pancreatic tissue regeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005055888030000081
    Figure BDA0005055888030000081
  • Figure BDA0005055888030000091
    Figure BDA0005055888030000091
  • Figure BDA0005055888030000171
    Figure BDA0005055888030000171
Patent Text Reader

Abstract

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also referred to as MHC class Ib molecules) in combination with peptide antigens for the treatment of type 1 diabetes mellitus (T1D). The present invention more specifically relates to recombinant polypeptides comprising a peptide antigen and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides and their use for the treatment of Type 1 diabetes mellitus (T1D).
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with peptide antigens for the treatment of type 1 diabetes (T1D). The present invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of non-classical MHC class Ib molecules. The present invention also relates to methods for producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use for the treatment of type 1 diabetes (T1D).

[0002] background

[0003] As in all autoimmune diseases, type 1 diabetes (T1D) is caused by an excessive immune response of the body to its own tissues, which are mistaken for foreign tissues and attacked. T cells play a decisive role here, and they are able to recognize single target structures (antigens) very selectively through their receptors. At present, such diseases are mainly treated with anti-inflammatory drugs or antibodies, which can systemically suppress the immune response, thereby alleviating symptoms or slowing down the progression of the disease. But at the same time, functional T cells are also crucial for the survival of patients with autoimmune diseases because they are able to recognize and fight dangerous viruses, bacteria, parasites and mutant cells. Therefore, systemic immunosuppression can only be used in a narrow therapeutic window. Therefore, in the case of T1D, one attempt is to partially compensate for the defects that have occurred by administering insulin in type 1 diabetes. However, blood sugar level monitoring and precise insulin dosing are very difficult. Therefore, the unmet medical needs are very high, and due to numerous sequelae, the life expectancy of T1D patients is reduced by 11-13 years (Livingstone et al, JAMA. 2015 Jan 6; 313 (1): 37-44).

[0004] CD8 T cells that attack pancreatic islet cells play a crucial role in T1D (Tsai S, Shameli A, Santamaria P. CD8+T cells in type 1 diabetes. Adv Immunol. 2008; 100: 79-124.)

[0005] However, one of the key diagnostic tools for T1D is the detection of autoantibodies in serum, such as islet cell cytoplasmic autoantibodies (ICA), glutamic acid decarboxylase autoantibodies (GADA), insulinoma-associated 2 autoantibodies (IA-2A), or insulin autoantibodies (IAA). In this way, patients at risk can be identified before severe destruction of islet cells occurs. In addition, inhibition of CD8 T cell responses and autoantibody formation can significantly improve disease outcomes.

[0006] WO 2018 / 215340 relates to the combination of MHC class Ib molecules and peptides for targeted therapeutic immunomodulation.

[0007] Overall, there remains a need for improved medications for the treatment of type 1 diabetes (T1D). Summary of the invention

[0008] The inventors have found that human MHC class Ib molecules, such as HLA-G, have the ability to induce antigen-specific tolerance to presented peptide antigens. Therefore, although the structure and sequence of MHC class Ib molecules are similar to those of classical human MHC class Ia molecules that induce antigen-specific immune responses, according to the present invention, MHC class Ib molecules can be advantageously used to suppress immune responses in an antigen-specific manner. In addition, the inventors have found that molecules other than naturally occurring MHC class Ib molecules, in particular polypeptides that only contain at least one domain of MHC class Ib molecules, preferably at least an α3 domain of MHC class Ib molecules, can be used to suppress immune responses as described in the present invention: the α1 and α2 domains of various class Ia molecules can be combined with the α3 domain of human MHC class Ib molecules to suppress immune responses to peptides presented by these antigens. The inventors have further found that antigens located in the HLA-G peptide binding groove induce selective tolerance in homologous T cells. The inventors have observed two mechanisms, including: in highly activated cytotoxic CD8 + Induction of apoptosis in T cells, as well as induction of regulatory T cells in cognate naive T cells. Thus, the present invention allows the induction of selective tolerance induction against specific antigens without compromising protective immune responses against pathogens.

[0009] HLA-G molecules loaded with antigens may be unstable. Therefore, the inventors have designed soluble recombinant polypeptides comprising a peptide antigen, an MHC class Ib molecule, such as HLA-G, and β2-microglobulin (b2m), and covalently linking these three components (e.g., via a covalent linker). Alternatively, the antigen-binding α1 and α2 domains of MHC class Ib molecules (e.g., HLA-G) are replaced with corresponding domains of other MHC molecules to enhance the flexibility and versatility of these recombinant polypeptides (e.g., see Figure 2 ). These alternative recombinant polypeptides can be designed with other antigen-binding domains of human HLA molecules. b The construct of the α1 and α2 domains can present the ovalbumin-derived peptide SIINFEKL to OT-1 T cells. (OT-1 T cells express a transgenic T cell receptor that specifically recognizes this antigen) (WO 2018 / 215340).

[0010] Surprisingly, the inventors have found that the use of the recombinant polypeptide of the present invention can inhibit immune responses to human proinsulin / human insulin (INS), human glutamic acid decarboxylase 65 (GAD65), human islet amyloid polypeptide (IAPP) and human zinc transporter 8 (ZNT8). Therefore, according to the present invention, the recombinant polypeptide of the present invention can treat type 1 diabetes (T1D).

[0011] Furthermore, according to the present invention, the recombinant polypeptide of the present invention not only regulates T cell responses, but also prevents the formation of autoantibodies against human proinsulin and human insulin (INS), human glutamic acid decarboxylase 65 (GAD65), human islet amyloid polypeptide (IAPP), and human zinc transporter 8 (ZNT8). This advantage is expected to contribute to clinical improvement in human patients with type 1 diabetes (T1D) because in addition to CD8 + In addition to T cells, such autoantibodies are also involved in the pathology of type 1 diabetes (T1D).

[0012] Therefore, the present invention relates to the following preferred embodiments:

[0013] 1. A recombinant polypeptide capable of presenting a peptide antigen, the recombinant polypeptide comprising, in order from N-terminus to C-terminus:

[0014] i) a peptide antigen presented by the recombinant polypeptide, wherein the peptide antigen is human proinsulin or a peptide of human insulin, human glutamic acid decarboxylase 65, human amylin or human zinc transporter 8;

[0015] ii) optionally, a linker sequence;

[0016] iii) optionally, a human polypeptide domain sequence, the human polypeptide domain sequence comprising a human β2 microglobulin sequence, or an amino acid sequence that is at least 90% identical to the human β2 microglobulin amino acid sequence shown in SEQ ID NO: 5;

[0017] iv) optionally, a linker sequence;

[0018] v) optionally, an α1 domain of an MHC molecule;

[0019] vi) optionally, an α2 domain of an MHC molecule;

[0020] vii) an α3 domain of an MHC class Ib molecule or a derivative of the α3 domain of an MHC class Ib molecule, said derivative being capable of binding to ILT2 or ILT4;

[0021] viii) optionally, a protease cleavage site;

[0022] ix) optionally, a spacer sequence; and

[0023] x) Optionally, an affinity tag.

[0024] 2. The recombinant polypeptide according to item 1, wherein the peptide antigen according to i) has a length of 7 to 11 amino acids, preferably a length of 8 to 10 amino acids.

[0025] 3. The recombinant polypeptide according to item 1 or 2, wherein the peptide antigen according to i) consists of an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO:2, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

[0026] 4. The recombinant polypeptide according to any one of the above items, wherein the peptide antigen consists of an amino acid sequence selected from the following group, the group consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 22 and SEQ ID NO: 23.

[0027] 5. The recombinant polypeptide according to any one of items 1 to 3, wherein the peptide antigen is a peptide antigen of human proinsulin or human insulin, and preferably consists of an amino acid sequence selected from the following group, the group consisting of the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 25.

[0028] 6. The recombinant polypeptide according to any one of items 1 to 3, wherein the peptide antigen is a peptide antigen of human glutamate decarboxylase 65, preferably consisting of an amino acid sequence selected from the following group, the group consisting of the amino acid sequences of SEQ ID NO: 23, SEQ ID NO: 26 and SEQ ID NO: 27.

[0029] 7. The recombinant polypeptide according to any one of items 1 to 3, wherein the peptide antigen is a peptide antigen of human glutamate decarboxylase 65, consisting of the amino acid sequence of SEQ ID NO: 26.

[0030] 8. The recombinant polypeptide according to any one of items 1 to 3, wherein the peptide antigen is a peptide antigen of human zinc transporter 8, and preferably consists of an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO: 22 and SEQ ID NO: 24.

[0031] 9. The recombinant polypeptide according to any one of items 1 to 3, wherein the peptide antigen is a peptide antigen of human amylin.

[0032] 10. The recombinant polypeptide according to any one of the above items, wherein the α1 domain according to (v) and the α2 domain according to (vi) are derived from human MHC class Ia molecules or from human MHC class Ib molecules.

[0033] 11. The recombinant polypeptide according to item 10, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human MHC class Ia molecules.

[0034] 12. The recombinant polypeptide according to item 11, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human HLA-A2 molecules.

[0035] 13. The recombinant polypeptide according to item 10, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human MHC class Ib molecules.

[0036] 14. The recombinant polypeptide according to item 13, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human HLA-G molecules.

[0037] 15. The recombinant polypeptide according to any one of the above items, wherein the α3 domain of the MHC class Ib molecule according to (vii) is the α3 domain of human HLA-E, human HLA-F or human HLA-G.

[0038] 16. The recombinant polypeptide according to any one of the above items, wherein the α3 domain of the MHC class Ib molecule according to (vii) is the α3 domain of human HLA-G.

[0039] 17. A recombinant polypeptide according to any of the above items, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 80% amino acid sequence identity, preferably at least 90% amino acid sequence identity, with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0040] 18. A recombinant polypeptide according to item 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 92% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0041] 19. A recombinant polypeptide according to item 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 94% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0042] 20. A recombinant polypeptide according to item 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 96% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21.

[0043] 21. A recombinant polypeptide according to item 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 98% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0044] 22. A recombinant polypeptide according to item 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 99% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0045] 23. The recombinant polypeptide according to item 17, wherein the α3 domain according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21.

[0046] 24. A recombinant polypeptide according to any of the above items, wherein the linker sequence according to (ii) and / or the linker sequence according to (iv) comprises the amino acid sequence (GGGGS)n, wherein n is an integer equal to or greater than 1.

[0047] 25. The recombinant polypeptide according to item 24, wherein the linker sequence according to (ii) comprises the amino acid sequence (GGGGS)n, wherein n is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and is preferably selected from the group consisting of 2, 3, 4 and 5.

[0048] 26. A recombinant polypeptide according to item 24 or 25, wherein the linker sequence according to (iv) comprises the amino acid sequence (GGGGS)n, wherein n is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and is preferably selected from the group consisting of 2, 3, 4 and 5.

[0049] 27. A recombinant polypeptide according to any of the above items, wherein the sequence of the human polypeptide domain according to (iii) is at least 95% identical to the amino acid sequence of SEQ ID NO:5, preferably at least 98% identical to the amino acid sequence of SEQ ID NO:5, and more preferably identical to the amino acid sequence of SEQ ID NO:5.

[0050] 28. The recombinant polypeptide according to any one of the above items, wherein the polypeptide is a dimer or a multimer.

[0051] 29. The recombinant polypeptide according to any one of the above items, wherein the polypeptide comprises or consists of all components i) to vii).

[0052] 30. The recombinant polypeptide according to any one of the above items, wherein the polypeptide does not comprise components viii) to x).

[0053] 31. The recombinant polypeptide according to any one of items 1 to 29, wherein the polypeptide comprises or consists of all components i) to x).

[0054] 32. The recombinant polypeptide according to any one of the above items, further comprising an N-terminal secretion signal peptide sequence.

[0055] 33. The recombinant polypeptide according to any one of items 1 to 31, wherein the recombinant polypeptide consists of the following amino acid sequence, which consists of the following ((a) and (b)) in order from N-terminus to C-terminus:

[0056] (a) a peptide antigen selected from the group consisting of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:2, and

[0057] (b) The amino acid sequence of SEQ ID NO:16.

[0058] 34. The recombinant polypeptide according to any of the above items, wherein the recombinant polypeptide is soluble.

[0059] 35. A nucleic acid encoding one or more polypeptides according to any one of the above.

[0060] 36. The nucleic acid according to item 35, wherein the nucleic acid is a vector.

[0061] 37. A pharmaceutical composition comprising at least one nucleic acid according to item 35 or 36.

[0062] 38. A pharmaceutical composition or kit comprising at least one recombinant polypeptide according to any one of items 1-34.

[0063] 39. The pharmaceutical composition or kit according to item 38, wherein the pharmaceutical composition or kit comprises at least two different recombinant polypeptides according to any one of items 1-34, and wherein each different polypeptide comprises a different peptide antigen as defined in any one of items 3-9.

[0064] 40. A pharmaceutical composition or kit according to item 38 or 39, wherein the pharmaceutical composition or kit comprises at least the following ((A) to (C)): (A) a recombinant polypeptide, wherein the peptide antigen is a peptide antigen of human proinsulin or human insulin; (B) a recombinant polypeptide, wherein the peptide antigen is a peptide antigen of human glutamate decarboxylase 65; (C) a recombinant polypeptide, wherein the peptide antigen is a peptide antigen of human zinc transporter 8; and optionally further comprises (D) a recombinant polypeptide, wherein the peptide antigen is a peptide antigen of human amylin.

[0065] 41. A pharmaceutical composition or kit according to any one of items 38 to 40, wherein the pharmaceutical composition or kit comprises at least three different recombinant polypeptides according to any one of items 1 to 34, wherein the peptide antigen of the first recombinant polypeptide among the at least three different recombinant polypeptides consists of the amino acid sequence of SEQ ID NO: 2, wherein the peptide antigen of the second recombinant polypeptide among the at least three different recombinant polypeptides consists of the amino acid sequence of SEQ ID NO: 22, and wherein the peptide antigen of the third recombinant polypeptide among the at least three different recombinant polypeptides consists of the amino acid sequence of SEQ ID NO: 23.

[0066] 42. The pharmaceutical composition or kit according to any one of items 37-41, for use in treating type 1 diabetes in human patients.

[0067] 43. The pharmaceutical composition or kit for use according to item 42, wherein the treatment is treatment by immunotherapy.

[0068] 44. A pharmaceutical composition or kit for use according to any one of items 42-43, wherein the treatment is carried out by inducing immune tolerance to human proinsulin and / or human insulin, human glutamic acid decarboxylase 65, human amylin and / or human zinc transporter 8.

[0069] 45. A pharmaceutical composition or kit for use according to any one of items 42-44, wherein the treatment is used to reduce the level of anti-insulin autoantibodies (insulin autoantibodies IAA), or glutamate decarboxylase (GAD-65), or islet antigen-2A (IA-2A), or zinc transporter ZnT8 in plasma, assessed by a radioactive binding assay or a non-radioactive electrochemiluminescent antigen binding assay.

[0070] 46. ​​A pharmaceutical composition or kit for use according to any one of items 42-45, wherein the human patient is a patient who has anti-insulin autoantibodies (insulin autoantibodies IAA), or glutamic acid decarboxylase (GAD-65), or islet antigen-2A (IA-2A), or zinc transporter ZnT8 in plasma before the start of treatment.

[0071] 47. A recombinant host cell comprising the nucleic acid or vector of item 35 or 36, and expressing the recombinant polypeptide of any one of items 1 to 34.

[0072] 48. A method for obtaining a pharmaceutical composition comprising a polypeptide according to any one of items 1 to 34, the method comprising the steps of: (a) culturing the recombinant host cell according to item 47 under conditions that allow expression of the recombinant polypeptide from the nucleic acid molecule, (a) recovering the recombinant polypeptide, (c) purifying the recombinant polypeptide, and (d) formulating the recombinant polypeptide into a pharmaceutical composition.

[0073] The pharmaceutical composition or kit used in the present invention can also be used to treat type 1 diabetes in human patients, wherein the treatment is combined with stem cell therapy for regenerating pancreatic tissue. It is expected that such combined therapy will be beneficial because the recombinant polypeptide of the present invention will promote the regeneration of pancreatic tissue by stem cell therapy due to its specific immunosuppressive effect.

[0074] The pharmaceutical composition or kit used in the present invention can also be used to treat type 1 diabetes in human patients, wherein the treatment is combined with stem cell therapy or human β cell regeneration drug therapy for regenerating pancreatic tissue. Human β cell regeneration drug therapy for diabetes has been described in P Wang, E Karakose, L Choleva, K Kumar, RJ DeVita., A Garcia- Reviewed in AF Stewart Andrew. Human Beta Cell Regenerative Drug Therapy for Diabetes: Past Achievements and Future Challenges. Frontiers in Endocrinology 12, 2021. DOI=10.3389 / fendo.2021.671946.

[0075] BRIEF DESCRIPTION OF THE DRAWINGS

[0076] Figure 1 : Description of peptide-loaded soluble MHC Ib molecules suitable for achieving therapeutic antigen-specific immunomodulation.

[0077] The presented peptide antigen is represented by a dotted sphere, the HLA-Gα1-3 domain is represented by a light grey, and the β2 microglobulin domain is represented by a dark grey. The optional linker connecting the antigenic peptide and the β2 microglobulin molecule is represented by a grey rod, and the optional disulfide bond capture is represented by a black sphere. This figure was generated using Pymol and was modified from the structures published in Clements et al., Proc Natl Acad Sci US A. 2005 Mar 1; 102(9): 3360-5 and Hansen et al., Trends Immunol. 2010 Oct; 31(10): 363-9.

[0078] Figure 2 : Examples of vector-based constructs encoding single-chain MHC Ib molecules suitable for therapeutic peptide-specific immunomodulation.

[0079] HLA-G1 and HLA-G5 each consist of three α domains (shown in black here), a non-covalently linked β2-microglobulin subunit (shown in dark gray here) and an antigenic peptide presented on HLA-G (short black arrow). HLA-G1 also contains a transmembrane domain and a short intracellular chain (not shown here). As shown, the α-3 domain is able to bind to the receptors ILT2 (see Shiroishi et al., Proc Natl Acad Sci US A. 2003 July 22; 100 (15): 8856-8861) and ILT4 (see Shiroishi et al., Proc Natl Acad Sci US A. 2006 Oct 31; 103 (44): 16412-7) on immune cells. Physiologically, these sequences form non-covalently linked MHC class 1 complexes. To simplify the purification of the composite MHC Ib molecule, one or more protein tags (e.g., SpotTag, myc tag, and / or His (6x) tag) can be introduced. These tags are introduced in such a way that they can be selectively removed by subsequent cleavage using an optional Factor Xa cleavage site. In addition, the antigenic peptide, β2-microglobulin, and MHC Ib α chain can be linked in sequence to improve stability. The vector map was generated using Snapgene Viewer software.

[0080] Figure 3 :The surrogate molecules of the recombinant polypeptide of the present invention can induce Tregs that secrete IL10 in mice. In this experiment, 100 μg of virus (Gp34) or ovalbumin (Ova) model peptide antigen, mouse H2-K b Surrogate molecules consisting of the α1 and 2 domains and the human HLA-G α3 domain and β2 microglobulin were injected intraperitoneally into 12-week-old C57BL / 6 mice. After 14 days, the mice were sacrificed and splenocytes were restimulated with 5 μg / ml of Gp34 or Ova peptides in a 48-hour standard murine IL-10 ELIspot assay. A significant increase in IL-10-secreting regulatory T cells was detected only when restimulated with the peptide to which tolerance was induced by the surrogate molecule injection.

[0081] (A) Experimental design; (B) Results

[0082] Figure 4 : The surrogate molecules of the recombinant polypeptides of the present invention can prevent CD8+T cell-driven EAE in mice.

[0083] In this mouse model of MS, the model antigen ovalbumin (OVA) is expressed in oligodendrocytes under the control of the myelin basic protein (MBP) promoter (ODC-OVA). This results in the presentation of the OVA257-264 peptide on the H-2Kb MHC molecule on oligodendrocytes. OT-I mice express a T cell receptor (OT-I) on their CD8+ T cells that accurately recognizes this peptide-MHC combination. When CD8+ T cells from these mice are transferred into 10-day-old ODC-OVA mice, these mice develop experimental autoimmune encephalomyelitis (EAE), whose pathogenesis and symptoms are similar to those of MS in many aspects (Na et al., Brain, Volume 131, Issue 9, September 2008, Pages 2353–2365). In this experiment, 500 μg of surrogate molecules consisting of viral (Gp34) or ovalbumin (Ova) model peptide antigens, mouse H2-K bα1 and 2 domains, and human HLA-Gα3 domain and β2 microglobulin or PBS alone were injected on the same day. EAE scoring was performed according to Bittner et al., J Vis Exp. 2014 Apr 15;(86):51275.

[0084] Only the replacement molecule that induced ovalbumin tolerance almost completely prevented EAE symptoms.

[0085] (A) Experimental design; (B) Results

[0086] Figure 5 : Some surrogate molecules of the recombinant polypeptides of the present invention selectively prevent CD4+ T cell-driven EAE in mice.

[0087] In this model, a strong myelin-specific autoimmune response was induced by administering MOG 35-55 peptide in combination with complete Freund's adjuvant (which activates CD4+ Th17 cells) and pertussis toxin (which makes the blood-brain barrier more permeable) (Protocol: Bittner et al., J Vis Exp. 2014 Apr 15; (86): 51275). Here, CD4+ cells and antibodies play a crucial role in the development of EAE (Tigno-Aranjuez et al., J Immunol November 1, 2009, 183 (9) 5654-5661). In addition, each mouse was injected with 100 μg of virus (Gp34) or two Mog peptide antigens (Mog37 or Mog44), mouse H2-D on the first day. b The α1 and 2 domains, as well as a surrogate molecule consisting of the human HLA-G α3 domain and β2 microglobulin, or PBS alone were injected.

[0088] Mog44 peptide containing the replacement molecule significantly alleviated EAE symptoms and weight loss.

[0089] (A) Experimental design; (B) EAE score; (C) Body weight

[0090] Figure 6 :The Mog44 replacement molecule of the recombinant polypeptide of the present invention can prevent inflammation and CD8 T cell infiltration in the spinal cord. (A) Toluidine; (B) CD8-DAB

[0091] 10 μm fresh frozen sections were stained with commercially available toluidine 1× staining reagent for 1 hour at room temperature. A large number of immune cell infiltrations were detected in EAE, but Mog44_Db_G could prevent this infiltration.

[0092] 10 μm fresh frozen sections were briefly dried at room temperature, fixed with acetone, blocked with 5% BSA 10% normal goat serum in PBS, and stained with 1:100 anti-CD8 antibody and secondary antibody coupled with HRP and DAB solution (detailed method: Karikari et al., Brain Behav Immun. 2022 Jan 12; 101:194-210)

[0093] Figure 7 : Detection of anti-MOG35-55 antibodies in Mog-EAE mice treated with the recombinant polypeptide replacement molecule of the present invention ("AIM Bio"

[0094] Briefly, mouse serum was collected by cardiac puncture after mice were sacrificed. 10 μg / ml Mog35-55 was used for overnight coating, wells were blocked with 1% BSA, and anti-Mog35-55 antibodies were detected with the indicated HRP-conjugated secondary antibodies. Figure 7 (Continued) shows that total IgG in these samples was not reduced by treatment with the MOG 47_Db_G surrogate molecule. TM Total IgG was quantified using the Human IgG (γ chain) detection kit (Thermo Fisher).

[0095] Figure 8 : List of candidate human T1D recombinant peptides. Correct protein folding is associated with good or at least acceptable expression. ELIspot assay found that the induction of Treg in PBMC was at least 30%, and the folding predicted by AlphaFold2 was also shown.

[0096] The recombinant polypeptides shown in the figure are as follows:

[0097]

[0098]

[0099] Fig. 9 :The recombinant polypeptide of the present invention upregulates CD8 Treg in healthy blood donors. The figure shows the upregulation of CD8+Treg cells by recombinant polypeptides containing zinc transporter 8 peptide antigen ILKDFSILL (A), insulin peptide antigen ALWGPDPAAA (B) and glutamic acid decarboxylase 65 peptide antigen EWESNGQPE (C).

[0100] Fig.10 :Purified single-chain MHC Ib molecules are stable monomers or dimers. Figure 3 and 4 After single-chain MHC Ib molecules in , the stability was analyzed after 1 and 3 freeze-thaw cycles, storage at room temperature for 5 days, and heating to 50°C for 30 minutes. To this end, under non-reducing conditions, A) 2 μg AIM Bio was used to perform Coomassie gel staining in 12% polyacrylamide gel, and B) 1 μg of protein was used to perform aHLA-G protein blotting (Western Blot) test using 2A12 aHLA-G antibody (1:1000). Both monomers and dimers can be detected.

[0101] Fig.11 :Single-chain MHC Ib molecules are thermally stable. For thermal shift analysis (TSA), 3 μg of the corresponding single-chain MHC Ib molecules or Motavizumab as a control molecule were diluted to a volume of 25 μl with PBS and 5×SYPRO Orange dye (stock solution 5000×, final concentration: 5×). The melting curve program was set up on the StepOnePlus instrument using StepOnePlus software 2.3. The starting temperature was 25°C for one minute, and then the temperature was increased at a rate of 1°C per minute to a final temperature of 95°C for 2 minutes, thereby measuring autofluorescence in arbitrary units. The data were exported and graphed in Prism V7.04. To determine the melting temperature (Tm), the Boltzman sigmoid function was used.

[0102] Fig.12 :Single-chain MHC Ib molecules induce Treg in a dose-dependent manner. OT-I mice were intraperitoneally injected with the indicated amount of single-chain H2_K bα1+2, HLA-Gα3 domain, human β2 microglobulin and the constructs of the indicated peptides, or vehicle (PBS). In these mice, Ova is the homologous peptide of the OT-I TCR and Gp34 is an unrelated virus-derived control peptide. After 14 days, mice were sacrificed and IL10-secreting cells in splenocytes were detected in a memory mouse IL-10 ELISpot (200,000 cells per well, MabTech mouse IL-10 ELISpot kit, supplemented with 5 μg / ml of the indicated peptide or PBS alone, 48 hours). A clear induction of IL-10-secreting cells reactive to the Ova peptide was observed when 50 and 500 μg of mouse-adapted Ova_KbG were injected.

[0103] Fig.13 :Single-chain MHC Ib molecules inhibit T cell lysis in a dose-dependent manner. OT1 / BL6 mice were sacrificed, spleen cells were collected and washed once in RPMI 5% FCS. Red blood cells were removed with 2 ml of 1× sterile RBC lysis buffer for 3 minutes. Cells were cultured at high density (10mio cells / ml) in RPMI 10% FCS medium for 72 hours, and the medium contained GMCSF 20ng / mL, IL-2 20ng / ml and IL-4 10ng / ml and increasing doses of Ova_KbG. Cells were then scraped from the plate and CD8+ cells were purified by magnetic beads.

[0104] Use a sterile 96-well white plate. Load Panc02 target cells expressing luciferase with 20 μg / ml Ova peptide (SIINFEKL) and shake at 500 rpm for 60 minutes at 37°C. Add CD8+ effector T cells and luciferin at a ratio of 50:1. Measure luminescence after 0h, 24h, and 48h.

[0105] Fig.14:Single-chain MHC Ib molecules induce IL-10 expression in EAE-ODC Ova mice. Serum cytokines from EAE-ODC Ova mice were measured using the Th1 / Th2 10plex Flowcytomix kit (eBioscience) according to the manufacturer's instructions. The kit was used to simultaneously detect mouse granulocyte-macrophage colony-stimulating factor (GMCSF), interleukin 1α (IL-1a), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), t interleukin-17 (IL-17), and tumor necrosis factor α (TNF-a) in a single sample. Beads coated with eight specific capture antibodies were mixed. Subsequently, 25 μL of mixed capture beads, 25 μL of unknown serum sample or standard dilution, and 25 μL of phycoerythrin (PE) detection reagent were added to each well of the 96V bottom plate in sequence, incubated at room temperature in the dark for 2 h, washed with 1 mL of washing buffer for 5 min, and centrifuged. The supernatant was discarded and the bead pellet was resuspended in 200 μL of buffer. The samples were measured on the Attune TM NxT flow cytometer and analyzed using the Attune flow cytometer software (Thermo Fisher Scientific).

[0106] Fig.15 : After treatment with the indicated single-chain MHC Ib molecules (recombinant polypeptides of the present invention), IL-10 secreting T cells increased.

[0107] The figure shows the percentage increase (%) of T cells secreting IL-10 after treatment with the indicated single-chain MHC Ib molecules. The black line represents HLA-A2 positive donors and the gray line represents negative donors. A significant increase in Tregs was observed in both HLA-A2 positive and negative donors (the response rate is shown in the legend).

[0108] Fig.16 :Thermal displacement analysis

[0109] For thermal shift analysis (TSA), 3 μg of single-chain MHC Ib molecules were diluted to a volume of 25 μl with PBS and 5× SYPRO Orange dye (stock solution 5000×, final concentration: 5×). The melting curve program was set up on the StepOnePlus instrument using StepOnePlus software 2.3. The starting temperature was 25°C for one minute, followed by an increase in temperature at a rate of 1°C per minute to a final temperature of 95°C for 2 minutes, thereby measuring autofluorescence in arbitrary units. Data were exported and graphed in Prism V7.04. To determine the melting temperature (Tm), the Boltzman sigmoid function was used. A high melting temperature indicates good protein stability and can be used for therapeutic purposes.

[0110] Fig.17 :Thermal stability test

[0111] A, C: Western blots of the indicated recombinant polypeptides. B, D: Coomassie gel electrophoresis of the indicated recombinant polypeptides (using the same method).

[0112] The data demonstrate that T1D single-chain MHC Ib molecules (recombinant polypeptides of the present invention) can be purified and stored and are able to withstand freeze-thaw cycles. DETAILED DESCRIPTION OF THE INVENTION

[0114] Definition and general techniques

[0115] Unless otherwise defined below, the terms used in the present invention should be understood according to the ordinary meaning known to those skilled in the art. All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety for all purposes. Publications cited herein may be cited by specifying complete references in the text.

[0116] All proteins of the present invention, including the recombinant polypeptides of the present invention, can be obtained by methods known in the art. Such methods include methods for producing recombinant polypeptides. The recombinant polypeptides of the present invention can be expressed in the recombinant host cells of the present invention. The recombinant host cells of the present invention are preferably mammalian cells, such as CHO and HEK cells.

[0117] It should be understood that the recombinant polypeptide of the present invention is intended to optionally include a secretion signal peptide sequence. Similarly, the recombinant polypeptide of the present invention is intended to also optionally include an affinity tag, such as for the convenience of purification, and an optional protease cleavage site between the tag and the polypeptide, such as for the convenience of removing the tag by protease cleavage.

[0118] It should also be understood that any amino acid sequence mentioned herein is intended to cover not only the unmodified amino acid sequence, but also typical post-translational modifications of these amino acid sequences that occur in cell expression systems known in the art (e.g., glycosylation or deamidation of amino acids, cleavage of specific amino acids or other post-translational modifications), including mammalian cells, such as CHO and HEK cells.

[0119] Likewise, it is to be understood that the recombinant polypeptides of the present invention are intended to optionally include the corresponding propeptides.

[0120] It should also be understood that the recombinant polypeptides of the present invention may be in a soluble form or in a membrane-bound form. The term "soluble" as used herein means that the recombinant polypeptide is soluble under the following reference conditions: 5 μg / ml to 5 mg / ml in PBS, optionally containing 0.1% human serum, or optionally in 50% glycerol. Whether the recombinant polypeptide is "soluble" under these conditions can be determined by methods known in the art, such as by measuring the turbidity of the recombinant polypeptide under the above-mentioned reference conditions. As used herein, soluble means that at least 95% of the recombinant polypeptide is determined to be soluble under these reference conditions. The single-chain MHC molecules can be stored, for example, at -80°C in PBS (depending on the protein concentration, 0.1% human albumin may be used as a carrier or not), or at -20°C in 50% glycerol.

[0121] According to the present invention, the MHC molecule is preferably a human MHC molecule.

[0122] The recombinant polypeptide of the present invention is preferably an isolated recombinant polypeptide.

[0123] It should be understood how to prepare recombinant polypeptides according to the present invention that can bind and present peptide antigens. For example, peptide antigen binding domains such as α1 and α2 domains are well known, and these domains can be modified. The ability of peptide antigens to bind to polypeptides of the present invention and MHC molecules can be determined by techniques known in the art, including but not limited to exploratory methods such as mass spectrometry and computer bioinformatics predictions after MHC peptide elution, and confirmatory methods such as MHC peptide multimer binding methods and stimulation tests.

[0124] According to the present invention, the recombinant polypeptide, pharmaceutical composition and kit of the present invention are preferably suitable for use in human patients.

[0125] According to the present invention, the recombinant polypeptide, pharmaceutical composition and kit of the present invention are preferably suitable for treating type 1 diabetes in human patients.

[0126] According to the present invention, the recombinant polypeptide, pharmaceutical composition and kit of the present invention are preferably suitable for inducing immune tolerance against human proinsulin or human insulin, human glutamic acid decarboxylase 65, human amylin or human zinc transporter 8, for example in human patients.

[0127] It should be understood that according to the present invention, the recombinant polypeptides, pharmaceutical compositions and kits of the present invention are stable.

[0128] It should be understood that for the peptide antigens used according to the present invention, any length of these peptide antigens mentioned herein (e.g. "length of 7 to 11 amino acids") refers to the length of the peptide antigen itself. Therefore, the length of the peptide antigen mentioned herein does not include the length conferred by additional amino acids that do not belong to the peptide antigen, such as additional amino acids from possible linker sequences, etc.

[0129] According to the present invention, each occurrence of the term "comprising" may optionally be replaced by the term "consisting of".

[0130] Methods and techniques

[0131] Generally, unless otherwise defined herein, the methods used in the present invention (e.g., cloning methods or methods related to antibodies) are performed according to procedures known in the art, such as those described in Sambrook et al. ("Molecular Cloning: A Laboratory Manual.", 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1989), Ausubel et al. ("Current Protocols in Molecular Biology." Greene Publishing Associates and Wiley Interscience; New York 1992), and Harlow and Lane ("Antibodies: A Laboratory Manual" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1988), all of which are incorporated herein by reference.

[0132] Protein-protein binding, e.g. binding of an antibody to its respective target protein, can be assessed by methods known in the art. Protein-protein binding is preferably assessed by surface plasmon resonance spectroscopy measurements.

[0133] For example, the binding of the MHC class Ib molecule or recombinant polypeptide according to the present invention to its receptor, including ILT2 and ILT4, is preferably assessed by surface plasmon resonance spectroscopy. More preferably, the binding of the MHC class Ib molecule or recombinant polypeptide according to the present invention to its receptor is assessed by surface plasmon resonance measurement at 25°C. Shiroishi et al., Proc Natl Acad Sci US A. 2003 July 22; 100(15): 8856-8861 describes suitable conditions for such surface plasmon resonance measurements.

[0134] The sequence alignment of the present invention is performed using the BLAST algorithm (see Altschul et al. (1990) "Basic local alignment search tool." Journal of Molecular Biology 215.p.403-410.; Altschul et al.: (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25: 3389-3402.). Suitable parameters for sequence alignment of short peptides using the BLAST algorithm, which are suitable for peptide antigens according to the present invention, are known in the art. Most software tools using the BLAST algorithm will automatically adjust the sequence alignment parameters for short input sequences. In one embodiment, the following parameters are used: Max target sequences 10; Word size 3; BLOSUM 62 matrix; gap costs: existence 11, extension 1; conditional compositional score matrix adjustment. Therefore, terms such as "identity" or "identical" when used in connection with a sequence preferably refer to identity values ​​obtained using the BLAST algorithm.

[0135] Preparation of the pharmaceutical composition of the present invention

[0136] The pharmaceutical composition of the present invention is prepared according to known pharmaceutical composition preparation standards.

[0137] For example, the pharmaceutical composition should be prepared in such a way that it can be easily stored and administered.The pharmaceutical composition of the present invention may therefore comprise pharmaceutically acceptable components, such as carriers, excipients and / or stabilizers.

[0138] Such pharmaceutically acceptable components are non-toxic in the amounts used when the pharmaceutical composition is administered to a human patient. The pharmaceutically acceptable components added to the pharmaceutical composition may depend on the chemical nature of the active ingredients present in the composition, the specific intended use of the pharmaceutical composition, and the route of administration.

[0139] In general, pharmaceutically acceptable components associated with the present invention are used according to existing knowledge in the art, such as from Remington's Pharmaceutical Sciences, Ed. AR Gennaro, 20th edition, 2000, Williams & Wilkins, PA, USA. Pharmaceutical compositions comprising nucleic acids (e.g., RNA) of the present invention can also be formulated according to existing knowledge in the art, such as using liposome formulations targeted to dendritic cells.

[0140] Peptide antigens according to the present invention

[0141] The peptide antigens that can be used according to the present invention, including the peptide antigens defined above, are not particularly limited except for their ability to be presented on MHC molecules. It should be understood that "peptide antigens presented by the recombinant polypeptide" in relation to the present invention refers to peptide antigens that the recombinant polypeptide presents to human T cells if such T cells are present.

[0142] As is known in the art, peptides capable of being presented on MHC molecules can be produced (see, e.g., Rammensee, Bachmann, Emmerich, Bachor, and Rock,Reits,Neefjes.PresentYourself! By MHC Class I and MHC Class II Molecules.Trends Immunol.2016Nov;37(11):724-737).

[0143] Peptide antigens are well known in the art. Typically, the peptide antigens according to the present invention are capable of binding to MHC class I proteins. It will be appreciated by those skilled in the art that for each MHC class Ib molecule or polypeptide capable of presenting a peptide according to the present invention, it is preferred to use a peptide antigen capable of binding to the MHC class Ib molecule or recombinant polypeptide. These peptide antigens can be selected according to methods known in the art.

[0144] The binding of a peptide antigen to an MHC class Ib molecule according to the present invention or a polypeptide capable of binding to a peptide antigen can be assessed by methods known in the art, such as the following method:

[0145] Rammensee,Bachmann,Emmerich,Bachor, SYFPEITHI:database forMHC ligands and peptide motifs.Immunogenetics.1999Nov;50(3-4):213-9;

[0146] Pearson et al.MHC class I-associated peptides derive from selective regions of the human genome.J Clin Invest.2016Dec 1;126(12):4690-4701; and

[0147] Rock,Reits,Neefjes.Present Yourself! By MHC Class I and MHC Class IIMolecules.Trends Immunol.2016Nov;37(11):724-737.

[0148] These methods include experimental approaches and methods for predicting peptide antigen binding.

[0149] Anchor residues for anchoring peptide antigens to MHC class I molecules and ensuring binding of peptide antigens to MHC class I molecules are known in the art.

[0150] In a preferred embodiment according to all embodiments of the present invention, the peptide antigen used according to the present invention comprises any anchor or preferred amino acid residues in the positions predicted for MHC class I molecules.

[0151] Preferably, such predictions are performed as described in any of the following publications:

[0152] -Rammensee et al, SYFPEITHI: database for MHCligands and peptidemotifs. Immunogenetics (1999) 50:213-219

[0153] -Nielsen et al,Protein Sci(2003)12:1007-1017

[0154] -Neefjes et al. Nat Rev Immunol.2011Nov 11;11(12):823-36

[0155] -Diehl et al.Curr Biol.1996Mar 1;6(3):305-14,

[0156] -Lee et al.Immunity.1995Nov;3(5):591-600.

[0157] -Desai&Kulkarni-Kale,T-cell epitope prediction methods:anoverview.Methods Mol Biol. 2014;1184:333-64.

[0158] -Jumper et al.Highly accurate protein structure prediction withAlphaFold.Nature2021;596:583–589

[0159] In the present invention, the peptide antigen is derived from human proinsulin or human insulin, human glutamic acid decarboxylase 65, human amylin or human zinc transporter 8.

[0160] It should be understood that the non-anchor amino acid residues of the peptide antigen of the present invention may or may not contain conservative substitutions, preferably no more than two conservative substitutions, and more preferably one conservative substitution, relative to the corresponding amino acid sequence of the peptide antigen from human proinsulin or human insulin, human glutamate decarboxylase 65, human amylin or human zinc transporter 8.

[0161] The peptide antigens of the present invention are preferably composed of naturally occurring amino acids. However, non-naturally occurring amino acids, such as modified amino acids, may also be used. For example, in one embodiment, the peptide antigens of the present invention include peptidomimetic peptides of the amino acid sequences of human proinsulin or human insulin, human glutamic acid decarboxylase 65, human amylin, or human zinc transporter 8.

[0162] Methods for the synthesis of peptide antigens, including peptide antigens according to the present invention, are well known in the art.

[0163] sequence

[0164] The preferred amino acid sequences mentioned in the present application can be independently selected from the following sequences: the sequences are represented in the order from N-terminus to C-terminus; and are represented by single-letter amino acid codes.

[0165] Exemplary sequences that are part of the recombinant polypeptides of the invention:

[0166] Optional leader peptide (deleted from recombinant polypeptide due to processing during cellular expression): e.g. MSRSVALAVLALLSLSGLEA (SEQ ID NO: 1)

[0167] Peptide antigen: Any MHC class I peptide corresponding to the MHC class I α1 & 2 domains, such as ALWGPDPAAA (SEQ ID NO: 2)

[0168] First linker: for example, GGGGSGGGGSGGGGS (SEQ ID NO: 3) or GCGASGGGGSGGGGS (SEQ ID NO: 4)

[0169] beta-2 microglobulin, such as:

[0170] IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM (SEQ ID NO: 5, human β2 microglobulin)

[0171] Second connector, for example:

[0172] GGGGSGGGGSGGGGSGGGGS(SEQ ID NO:6)

[0173] The α1 and 2 domains are derived from human HLA-G or any other MHC class I α1 & 2 domains suitable for presenting the selected antigenic peptide. In the DT variant, Y84 may be C

[0174] For example, the α1 & 2 domains from human HLA-G: e.g.

[0175] GSHSMRYFSAAVSRPGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGCYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRA(SEQ ID NO:7)

[0176] Or: Human HLA-A2 α1&2 domains: e.g.

[0177] GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGCYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRT(SEQ ID NO:8)

[0178] Human HLA-G α3 domain (or any MHC Ib α3 domain, such as HLA-F, which also interacts with ILT2 and ILT4 receptors), for example:

[0179] DPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDL (SEQ ID NO: 9; HLA-Gα3 sequence).

[0180] Note that the following underlined amino acids in this sequence are involved in ILT2 or ILT4 receptor interaction:

[0181] DPPKTHVTHH PVFDYE ATLRCWALGFYPAEIILTWQRDGEDQTQD V ELVETRPAGDGTFQKWAAV V VPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDL

[0182] In addition, a shorter form of the human HLA-Gα3 domain may be used that lacks the alternative C-terminal amino acid sequence from intron 4 (SKEGDGGIMSVRESRSLSEDL; SEQ ID NO:20), namely:

[0183] DPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRW(SEQ ID NO:21),

[0184] Factor Xa restriction site: IEGRTGTKLGP (SEQ ID NO: 10)

[0185] SpotTag: PDRVRAVSHWSSC(SEQ ID NO:11)

[0186] Myc tag: EQKLISEEDL (SEQ ID NO: 12)

[0187] His tag: HHHHHH* (SEQ ID NO: 13)

[0188] Spacer sequence: for example NSAVD (SEQ ID NO: 14) or GS

[0189] The most preferred exemplary peptide antigens that can be part of the recombinant polypeptide of the present invention are as follows:

[0190]

[0191] Further preferred exemplary peptide antigens that may be part of the recombinant polypeptide of the present invention are as follows:

[0192]

[0193] Examples of recombinant polypeptides of the invention (with optional leader peptides):

[0194] MSRSVALAVLALLSLSGLEAALWGPDPAAAGGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTE KDEYACRVNHVTLSQPKIVKWDRDMGGGGSGGGGSGGGGSGGGGSGSHSMRYFFTSVSRPGRGEPRIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHR VDLGTLRGCYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDPPKTHVTHHPVF DYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC*(SEQ ID NO:15; note that the asterisk indicates the stop codon)

[0195] Note that the peptide antigen sequence of the above-mentioned full-length recombinant polypeptide can be replaced by any peptide antigen sequence according to the present invention, that is, replaced by any peptide antigen presented by the recombinant polypeptide, wherein the peptide antigen is a peptide of human proinsulin or human insulin, a peptide of human glutamic acid decarboxylase 65, a peptide of human amylin, or a peptide of human zinc transporter 8. That is, the recombinant polypeptide of the present invention can be composed of the following sequence, which consists of a peptide antigen that is a peptide of human proinsulin or human insulin, a peptide of human glutamic acid decarboxylase 65, a peptide of human amylin, or a peptide of human zinc transporter 8 (for example, any one of the peptide antigens of SEQ ID NOs: 2, 22, 23, 24, 25, 26, and 27), followed by the following sequence:

[0196] GCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDR DMGGGGSGGGGSGGGGSGGGGSGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGCYNQSEAG SHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC* (SEQ ID NO: 16; note, asterisk indicates stop codon)

[0197] The recombinant polypeptides of the present invention may also contain an optional leader peptide as exemplified above.

[0198] The receptors ILT2 (also known as LILRB1) and ILT4 (also known as LILRB2) are known in the art. According to the present invention, the preferred sequences of these receptors are as follows:

[0199] ILT2:

[0200] MTPILTVLICLGLSLGPRTHVQAGHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRL YREKKTALWITRIPQELVKKGQFPIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAYIKPTLSAQPSPVVNSGGNVILQCDSQVAFDGFSLCKEGEDEHPQCLNSQPHARGSSRAIFSVGPVSPSRRWWYRCYAYDSNSPYEWSLPSDLLELLVLGVSKKPSLSVQPGPIVAPEETLTLQCGSDAGYNRFVLYKDGERDFLQLAGAQPQAGLSQANFTLGPVSRSYGGQYRCYGA HNLSSEWSAPSDPLDILIAGQFYDRVSLSVQPGPTVASGENVTLLCQSQGWMQTFLLTKEGAADDPWRLRSTYQSQKYQAEFPMGPVTSAHAGTYRCYGSQSSKPYLLTHPSDPLELVVSGPSGGPSSPTTGPTSTSGPEDQPLTPTGSDPQSGLGRHLGVVIGILVAVILLLLLLLLLFLILRHRRQGKHWTSTQRKADFQHPAGAVGPEPTDRGLQWRSSPAADAQEENLYAAVKHTQPEDGVEMDTRSPHDEDPQAVTYAEVKHSRPRREMASPPSPLSGEFLDTKDRQAEEDRQMDTEAAASEAPQDVTYAQLHSLTLRREATEPPPSQEGPSPAVPSIYATLAIH(SEQ ID NO:17)

[0201] ILT4:

[0202] MTPIVTVLICLGLSLGPRTHVQTGTIPKPTLWAEPDSVITQGSPVTLSCQGSLEAQEYRLYREKKSASWITRIRPELVKNGQFHIPSITWEHTGRYGCQYYSRARWSELSDPLVLVMTGAYPKPTLSAQPSPVVTSGGRVTLQCESQVAF GGFILCKEGEEEHPQCLNSQPHARGSSRAIFSVGPVSPNRRWSHRCYGYDLNSPYVWSSPSDLLELLVPGVSKKPSLSVQPGPVVAPGESLTLQCVSDVGYDRFVLYKEGERDLRQLPGRQPQAGLSQANFTLGPVSRSYGGQYRCYGAH NLSSECSAPSDPLDILITGQIRGTPFISVQPGPTVASGENVTLLCQSWRQFHTFLLTKAGAADAPLRLRSIHEYPKYQAEFPMSPVTSAHAGTYRCYGSLNSDPYLLSHPSEPLELVVSGPSMGSSPPPTGPISTPAGPEDQPLTPTGSDP QSGLGRHLGVVIGILVAVVLLLLLLLLLFLILRHRRQGKHWTSTQRKADFQHPAGAVGPEPTDRGLQWRSSPAADAQEENLYAAVKDTQPEDGVEMDTRAAASEAPQDVTYAQLHSLTLRRKATEPPPSQEREPPAEPSIYATLAIH(SEQ ID NO:18)

[0203] The sequences of human proinsulin and human insulin, human glutamic acid decarboxylase 65, human amylin and human zinc transporter 8 are known in the art, and the preferred amino acid sequences of these proteins are as follows:

[0204] Human proinsulin and human insulin:

[0205] Full-length human insulin (consisting of 24aa signal peptide, 30aa B-chain, 31aa C-peptide, 21aa A-chain)

[0206] Reference sequence>sp|P01308|INS_HUMAN Insulin OS=Homo sapiens OX=9606GN=INSPE=1SV=1

[0207] MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN

[0208] (SEQ ID NO:19)

[0209] Proinsulin (after signal peptide cleavage)

[0210] FVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN

[0211] (SEQ ID NO:28)

[0212] Mature insulin (B chain and A chain)

[0213] FVNQHLCGSHLVEALYLVCGERGFFYTPKT(B chain)(SEQ ID NO:29)

[0214] LQKRGIVEQCCTSICSLYQLENYCN(A chain)(SEQ ID NO:30)

[0215] Human glutamate decarboxylase 65 (GAD65):

[0216] >NP_001127838.1glutamate decarboxylase 2[Homo sapiens]

[0217] MASPGSGFWSFGSEDGSGDSENPGTARAWCQVAQKFTGGIGNKLCALLYGDAEKPAESGGSQPPRAAARK

[0218] AACACDQKPCSCSKVDVNYAFLHATDLLPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNE

[0219] LLQEYNWELADQPQNLEEILMHCQTTLKYAIKTGHPRYFNQLSTGLDMVGLAADWLTSTANTNMFTYEIA

[0220] PVFVLLEYVTLKKMREIIGWPGGSGDGIFSPGGAISNMYAMMIARFKMFPEVKEKGMAALPRLIAFTSEH

[0221] SHFSLKKGAAALGIGTDSVILIKCDERGKMIPSDLERRILEAKQKGFVPFLVSATAGTTVYGAFDPLLAV

[0222] ADICKKYKIWMHVDAAWGGGLLMSRKHKWKLSGVERANSVTWNPHKMMGVPLQCSALLVREEGLMQNCNQMHASYLFQQDKHYDLSYDTGDKALQCGRHVDVFKLWLMWRAKGTTGFEAHVDKCLELAEYLYNIIKNREG

[0223] YEMVFDGKPQHTNVCFWYIPPSLRTLEDNEERMSRLSKVAPVIKARMMEYGTTMVSYQPLGDKVNFFRMV

[0224] ISNPAATHQDIDFLIEEIERLGQDL

[0225] (SEQ ID NO:31; note that glutamate decarboxylase 2 / GAD2 is a synonym for GAD65)

[0226] Human Amylin:

[0227] >NP_000406.1islet amyloid polypeptide preproprotein[Homo sapiens]

[0228] MGILKLQVFLIVLSVALNHHLKATPIESHQVEKRKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY

[0229] GKRNAVEVLKREPLNYLPL

[0230] (SEQ ID NO:32)

[0231] Human zinc transporter 8:

[0232] >NP_776250.2zinc transporter 8isoform a[Homo sapiens]

[0233] MEFLERTYLVNDKAAKMYAFTLESVELQQKPVNKDQCPRERPEELESGGMYHCHSGSKPTEKGANEYAYA

[0234] KWKLCSASAICFIFMIAEVVGGHIAGSLAVVTDAAHLLIDLTSFLLSLFSLWLSSKPPSKRLTFGWHRAE

[0235] ILGALLSILCIWVVTGVLVYLACERLLYPDYQIQATVMIIVSSCAVAANIVLTVVLHQRCLGHNHKEVQA

[0236] NASVRAAFVHALGDLFQSISVLISALIIYFKPEYKIADPICTFIFSILVLASTITILKDFSILLMEGVPK

[0237] SLNYSGVKELILAVDGVLSVHSLHIWSLTMNQVILSAHVATAASRDSQVVRREIAKALSKSFTMHSLTIQ

[0238] MESPVDQDPDCLFCEDPCD

[0239] (SEQ ID NO:33)

[0240] The present invention is further illustrated by the following non-limiting examples: Example

[0241] Embodiment 1:

[0242] Method for producing the recombinant polypeptide of the present invention

[0243] -Expi-293F cells (Thermo Fisher), in Expi-293 TM Growth in expression medium (Thermo Fisher): using Expifectamine TM 293 transfection kit (Thermo Fisher), DNA was complexed with Expifectamine using Opti-MEM (Thermo Fisher), and 1 μg of DNA was transfected into 2.5×10 6 After 18-20 hours, enhancers were added according to the protocol, and supernatants were harvested 4-6 days later (37°C, 8% CO2, humidified incubator). 2 Orbital shaker 125rpm

[0244] - Spot-tag protein purification: Spot-Cap resin equilibration: transfer the required amount of slurry to an appropriate tube, pellet the beads by centrifugation (4°C, 4 min, 2500 g), remove and discard the supernatant, add 10 bed volumes of PBS (cold) to the beads, invert to mix, pellet the beads by centrifugation (4°C, 4 min, 2500 g), remove and discard the supernatant, repeat 2 times

[0245] - Add the required volume of beads to the supernatant, incubate at 4°C on a rotator, wash the beads by repeated centrifugation (4°C, 4 min, 2500 g), and then remove the supernatant

[0246] - Prepare a 500 μM spot-peptide solution in PBS, remove the supernatant, and incubate with 1 / 3rd spot-peptide solution for 5-10 min

[0247] Beads were pelleted by centrifugation. Protein concentration was performed using an Amicon Ultra-4 centrifugal filter (15 kDa cutoff) and spot peptides were removed using a 15 kDa Amicon cutoff column.

[0248] Amicon Ultra-4 centrifugal filters (15 kDa cut-off) were rinsed with PBS and then with 0.1 N NaOH (centrifugation at 4000 g, 4°C) to remove traces of glycerol.

[0249] ELISPOT method:

[0250] 1) Cell culture

[0251] A) PBMC isolation (under laminar flow hood)

[0252] To isolate peripheral blood mononuclear cells (PBMCs), density centrifugation was performed using leukocytes from a leukocyte reduction chamber and a density gradient medium (e.g., Ficoll or ROTI Sep 1077). Cells were centrifuged at 1200 × g for 20 min without stopping, and then the interphase rings were collected and washed with 1 × PBS (5 min, 300 × g). PBMCs were frozen until further use.

[0253] B) PBMC pulse (under laminar flow hood)

[0254] PBMCs were thawed 1 day before PBMC pulse (d-1) and stored in 5 ml X-VIVO 15 medium containing 5% human AB serum in wells of 6-well plates at 37°C overnight.

[0255] The next day (d0), the cells were counted and suspended in X-VIVO 15 complete medium (5% hAB serum and cytokine mixture: 20 ng / ml hIL-2, 20 ng / ml hGM-CSF, 10 ng / ml hIL-4 and 10 ng / ml hTGF-b1) at a cell density of 3 × 10 6 cells / ml.

[0256] In the experiment, 3×10 6 Each cell was seeded in the corresponding wells of a 12-well plate in a final volume of 1000 μl X-VIVO complete medium containing a cytokine cocktail and 5 μg / ml AIM Bio molecules or corresponding controls.

[0257] On day 3, 1 ml of complete medium (containing cytokines) was added, and on day 6, a second pulse (after removal of medium) was performed with 5 μg / ml of the recombinant polypeptide of the present invention or its surrogate molecule (collectively referred to as "AIM Bio" molecules). On days 7, 10, and 12, 1 ml of complete medium (containing cytokines) was added.

[0258] Required:

[0259] X-VIVO 15 medium + 5% human AB serum

[0260] X-VIVO 15 complete medium: X-VIVO 15 medium + 2% human AB serum, supplemented with cytokine mixture: 10ng / ml TGF-b1, 10ng / ml IL-4, 20ng / ml IL-2, 20ng / ml GM-CSF

[0261] 6-well plate

[0262] 12-well plate

[0263] 2) ELISPOT

[0264] Laminar flow hood

[0265] On day 13, ELISPOT plates were coated with anti-hIL10 (clone 9D-7, diluted 1:500 in PBS, sterile filtered) and aIL10 (10G8-biotin), and on day 14, 200,000 cells were seeded per well on the ELISPOT plates in duplicate, including a negative control (cells plus PBS) and a positive control (e.g., LPS).

[0266] The PFDF membrane was activated with 50 μl / well EtOH (35% v / v) for 1 minute and then washed 5 times with 200 μl distilled sterile water. The plate was coated with 100 μl / well antibody solution at 4°C overnight. The next day, unbound coating antibody was removed, 5 washing steps were performed with 200 μl PBS, and 200 μl blocking buffer (X-VIVO 15 5% hAB serum) was added, and the plate was incubated at room temperature for 30 minutes-2 hours.

[0267] Prepare DMSO or DMSO containing the corresponding antigen peptide (e.g., MOG157) as a control, the final amount of peptide added is 5 μg peptide / ml, and the final volume is 100 μl / well. 150,000 cells are seeded per well in X-VIVO 15 medium containing 5% human AB serum. Carefully remove the blocking buffer (X VIVO 15 medium + 5% hAB serum), use a medium containing PBS as a negative control, and add the stimulator (total volume per well is 5 μg / ml) to other wells and incubate overnight at 37°C.

[0268] Outside the laminar flow hood

[0269] Secondary antibodies were prepared: 1 μg / ml aIL-10-biotinylated antibody and horseradish peroxidase-conjugated streptavidin (1:750 in 0.5% BSA / PBS) in 0.5% BSA / 1×PBS (1:1000 dilution). The tetramethylbenzidine solution was filtered using a 0.45 μm filter and stored at 4°C until use.

[0270] Remove the cell supernatant and wash five times with 100 μl PBS. Finally, wipe off the excess buffer with a paper towel.

[0271] 25 μl of diluted HRP-streptavidin (1:750) was added to each well and incubated for 1 hour at room temperature in the dark, followed by 5 washes with sterile 1× PBS.

[0272] Add 100 μl of filtered TMB substrate to each well and react for 15-25 minutes until blue spots appear. Rinse the wells thoroughly with tap water to terminate the reaction.

[0273] Remove the board's plastic drain and rinse the bottom and sides of the board with tap water and allow to dry.

[0274] Plate data were read using an ImmunoSpot S6 Ultra-V analyzer (Cellular Technology Limited), analyzed in Excel, and graphs / statistics were plotted in Graphad Prism.

[0275] Required:

[0276] Capture antibodies: anti-hIL10 (clone: ​​9D-7, Mabtech #3430-3-250; 1:500 dilution), anti-hIL10-biotinylated (Mabtech, #3430-6-250)

[0277] 1× PBS (sterile)

[0278] 35% ethanol (vol / vol)

[0279] Blocking buffer: X-vivo 5% hAB serum (sterile) [Block in the same medium as the cell culture medium]

[0280] Dilution buffer: 0.5% BAS in PBS

[0281] Washing buffer: 1× PBS

[0282] Culture medium: For T cells, X-VIVO 15 medium (Lonza)

[0283] Filter syringe: Millex GV

[0284] ELISPOT PVDF Plate (#MSIP4510, Millipore)

[0285] TMB substrate

[0286] Example 2: Alternative molecules of the recombinant polypeptide of the present invention induce Tregs that secrete IL10 in mice

[0287] Wild-type black 6 mice were injected with 100 μg of a recombinant polypeptide (also called "AIMBio") having the following sequence,

[0288] Ova_KbG

[0289] SIINFEKLGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQSFRVDLRTLLGCYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGCDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC(SEQ ID NO:34)

[0290] and

[0291] Gp34_KbG

[0292] AVYNFATMGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPK IVKWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQSFRVDLRTLLGCYN QSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGCDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDPPKTHVTHHPVFDYEAT LRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC(SEQ ID NO:35),

[0293] They were used to induce tolerance to OVA peptide or viral Gp34 peptide, respectively. Gp34 peptide is a well-characterized T cell epitope derived from the lymphocytic choriomeningitis virus (LCMV) glycoprotein. Although this antigen was traditionally referred to as Gp33, it was later discovered that H2-K b The epitope presented on H2-K d The presented epitope starts at amino acid 33. ) Therefore, we will H2-K b The epitope was named Gp34, which is in line with the latest recommendations. However, the use of the nomenclature of Gp33 and Gp34 in the literature is still unclear. The first 8 amino acids of SEQ ID NO:35 show the correct sequence (AVYNFATM; SEQ ID NO:58). Mice were sacrificed 2 weeks later and spleen cells were restimulated with matched or mismatched peptides. IL-10 secreting cells were quantified by ELIspot. The results are shown in Figure 3 shown.

[0294] Example 3: Alternative molecules of the recombinant polypeptides of the present invention selectively prevent CD8+ T cell-driven EAE in mice

[0295] As described in (Na et al, Brain. 2008 Sep; 131(Pt 9): 2353-65.), the bAdoptive transfer of CD8+ OT-I T cells that recognize ovalbumin epitopes in the context of WT mice into mice expressing ovalbumin in their oligodendrocytes resulted in experimental autoimmune encephalomyelitis, which recapitulates many of the symptoms of MS and late-stage NMO. In this animal model, a single injection of 500 μg of a recombinant peptide replacement molecule that induces tolerance to a targeted ovalbumin epitope (also called “AIMBio”) almost completely prevented EAE symptoms, whereas a replacement molecule presenting a control peptide had no significant protective effect ( Figure 4 ). The sequence of the recombinant polypeptide replacement molecule is as follows:

[0296] Mog44_DbG

[0297] FSRVVHLYRNGGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLS QPKIVKWDRDMGGGGSGGGGSGGGGSGGGGSGPHSMRYFETAVSRPGLEEPRYISVGYVDNKEFVRFDSDAENPRYEPRAPWMEQEGPEYWERETQKAKGQEQWFRVSLRNLLGC YNQSAGGSHTLQQMSGCDLGSDWRLLRGYLQFAYEGRDYIALNEDLKTWTAADMAAQITRRKWEQSGAAEHYKAYLEGECVEWLHRYLKNGNATLLRTDPPKTHVTHHPVFDYEA TLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC(SEQ ID NO:36)

[0298] Mog37_DbG

[0299] VGWYRSPFSRGCGASGGGGSGGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLS QPKIVKWDRDMGGGGSGGGGSGGGGSGGGGSGPHSMRYFETAVSRPGLEEPRYISVGYVDNKEFVRFDSDAENPRYEPRAPWMEQEGPEYWERETQKAKGQEQWFRVSLRNLLGC YNQSAGGSHTLQQMSGCDLGSDWRLLRGYLQFAYEGRDYIALNEDLKTWTAADMAAQITRRKWEQSGAAEHYKAYLEGECVEWLHRYLKNGNATLLRTDPPKTHVTHHPVFDYEA TLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC(SEQ ID NO:37)

[0300] Example 4: Some recombinant polypeptide surrogate molecules of the present invention selectively prevent CD4+ T cell-driven EAE in mice

[0301] On the day of intraperitoneal injection of 33 μg or 100 μg of the recombinant polypeptide replacement molecule of the present invention ("AIM Bio"), 100 μl of MOG35-55 peptide / CFA (complete Freund's adjuvant; the final concentration of Mycobacterium tuberculosis H37RA and peptide was 1 mg / ml) emulsion was injected subcutaneously on the left and right sides, respectively, and 250 ng of pertussis toxin (in 200 μl PBS) was injected intraperitoneally. The second pertussis toxin injection was performed 3 days later. In this animal model, a single injection of the AIM Bio replacement molecule (Mog44_Kb_G) that induces tolerance to the Mog epitope can significantly alleviate EAE symptoms, while replacement molecules presenting a control peptide (Gp34) or a non-functional Mog peptide (Mog37) have no significant protective effect ( Figure 5 In this model, Mog44 AIM Bio also prevented inflammation and CD8 T cell infiltration in the spinal cord ( Figure 6 ). The sequence of the recombinant polypeptide replacement molecule is shown in Example 3.

[0302] In this model, Mog44 AIM Bio also completely prevented the formation of MOG-specific autoantibodies in serum, as tested by ELISA ( Figure 7). This strongly suggests that the recombinant polypeptides of the invention are effective treatments for NMO, which is often characterized by an antibody response to human aquaporin 4, and for other autoimmune diseases, such as type 1 diabetes, whose pathology is also characterized by the presence of autoantibodies. Thus, the patient population is defined by common autoimmune-associated antigens. Certain MHC molecules are also associated with NMO.

[0303] Mog-reactive antibodies in mouse sera treated with AIM Bio (33 or 100 μg) were detected by standard ELISA protocol, with 3 washes between each step. Briefly, ELISA plates were coated with 10 μg / ml Mog35-55 peptide, blocked with PBS1% BSA, and then mouse sera diluted 1:25 in PBS1% BSA were added for 1 hour. Anti-mouse IgG-HRP or anti-mouse heavy and light chain-HRP antibodies diluted 1:5000 were used for detection.

[0304] Example 5: Human recombinant polypeptide candidates for treating type 1 diabetes of the present invention

[0305] The recombinant polypeptides of the present invention are newly developed protein complexes derived from the pregnancy-related immunosuppressive MHC molecule HLA-G. HLA-G may enable the embryo to influence the maternal immune system, making it tolerant to embryonic antigens but further antagonizing pathogen antigens. The recombinant polypeptides of the present invention containing various peptides can selectively eliminate peptide-specific cytotoxic effector T cells and induce peptide-specific regulatory T cells in vitro.

[0306] T1D autoantigens according to the present invention include (pro)insulin (INS), glutamic acid decarboxylase 65 (GAD65), islet amylin (IAPP) or zinc transporter 8 (ZNT8).

[0307] Figure 8 Shown is a list of human T1D recombinant polypeptide candidates.

[0308] The inventors' results showed that single-chain proteins containing INS, GAD65, IAPP or ZNT8 peptide antigens and HLA-Gα3 domains can induce tolerant T cells in healthy blood donors. Thus, CD8 Tregs were upregulated by at least 30% ( Fig. 9 ).

[0309] Correlating with the in vivo experiments shown here, it is plausible that these constructs inhibit both CD8 T cell-mediated and antibody-mediated responses against patient islet cell antigens.

[0310] Example 6: Further proof of concept of the stability and effect of the recombinant polypeptides of the present invention.

[0311] In addition, the inventors set out to obtain and test recombinant polypeptides having the general structure of the recombinant polypeptides of the present invention but containing various different peptide antigens in order to obtain further proof of concept that the recombinant polypeptides of the present invention and their surrogate molecules are stable and effective. Fig.10 and 11 As shown in Figure 2, the tested recombinant polypeptides were stable during freeze-thaw and storage and were thermostable. In addition, they induced Tregs ( Fig.12 ) and inhibited T cell lysis in a dose-dependent manner ( Fig.13 ). Fig.14 The effects of recombinant peptides on the serum cytokine profile of EAE-ODC Ova mice are shown. IL-10 and possibly IL-4 are induced, both known immunosuppressive cytokines that downregulate immune responses in an inflammatory setting. This requires the HLA-G α3 domain plus the cognate peptide. Induction of IL-2 appears to be caused when the cognate peptide is presented to the cells independent of the α3 domain. IL-2 is required for T cell activation and survival.

[0312] also, Fig.16 The high melting temperature shown confirms that the recombinant polypeptide of the present invention has good protein stability for therapeutic use. Fig.17 The data in show that T1D single-chain MHC Ib molecules (recombinant polypeptides of the present invention) can be purified and stored and can withstand freeze-thaw cycles.

[0313] Example 7: Fig.15 As shown, the recombinant polypeptide of the present invention up-regulated CD8 Treg in PBMCs of healthy blood donors.

[0314] In vitro Treg induction mediated by peptide-HLA-G constructs (AIM Biologicals) was performed as follows: PBMCs from healthy donors were purified by density centrifugation of leukocytes from leukocyte reduction chambers using Ficoll. Cells were centrifuged at 1200×g for 20 minutes without interruption, and then the interphase ring was collected and washed with 1× PBS (5 minutes, 300×g). PBMCs were frozen for future use.

[0315] PBMCs were thawed 1 day before PBMC pulse (d-1) and stored in 5 ml X-VIVO 15 medium containing 5% human AB serum in wells of 6-well plates at 37°C overnight.

[0316] On the next day (d0), the cells were counted and suspended in X-VIVO 15 complete medium (5% hAB serum and cytokine mixture: 20 ng / ml hIL-2, 20 ng / ml hGM-CSF, 10 ng / ml hIL-4 and 10 ng / ml hTGF-b1) at a cell density of 3 × 10 6 For the experiment, 3×10 6 Each cell was seeded into the corresponding wells of a 12-well plate in a final volume of 1000 μl X-VIVO complete medium containing cytokine cocktail and 5 μg / ml AIM Bio molecules or corresponding controls.

[0317] On day 3, add 1 ml of complete medium (with cytokines), and on day 6, add 5 μg / ml AIM Bio molecules for the second pulse (after removing the medium). On days 7, 10, and 12, add 1 ml of complete medium (with cytokines).

[0318] On day 13, the ELISpot plate PVDF membrane was activated with 50 μl / well EtOH (35% v / v) for 1 minute, and then washed 5 times with 200 μl distilled sterile water. The plate was coated with 100 μl / well anti-hIL10 (clone 9D-7, diluted 1:500 in PBS, sterile filtered) at 4°C overnight. The next day, the unbound coating antibody was removed, 5 washing steps were performed with 200 μl PBS, and 200 μl blocking buffer (X-VIVO 15 5% hAB serum) was added, and the plate was incubated at room temperature for 30 minutes-2 hours. On day 14, 200,000 cells were seeded per well on the ELISpot plate in duplicate, including negative controls (cells plus PBS) and positive controls (e.g., LPS), and incubated for 48 hours. Prepare secondary antibodies: 1 μg / ml aIL-10-biotinylated antibody and horseradish peroxidase-conjugated streptavidin (1:750 in 0.5% BSA / PBS) in 0.5% BSA / 1×PBS (1:1000 dilution), tetramethylbenzidine solution was filtered using a 0.45 μm filter and stored at 4°C until use. Remove cell supernatant and wash 5 times with 100 μl PBS. Use paper towel to remove the final excess buffer. Add 25 μl diluted HRP-streptavidin (1:750) to each well, incubate in the dark at room temperature for 1 hour, and then wash 5 times with sterile 1×PBS. Add 100 μl filtered TMB substrate to each well and incubate for 15-25 minutes until blue spots appear. Wash the wells thoroughly with water to stop the reaction. Remove the plastic drain of the plate and rinse the bottom and sides of the plate with tap water and let it dry.

[0319] Some recombinant polypeptides of the present invention induce at least a 30% increase in IL-10 secreting Tregs in about 75% of PBMCs of healthy blood donors.

[0320] Industrial Applicability

[0321] The pharmaceutical compositions, polypeptides, nucleic acids, cells and products used in the present invention have industrial application value, for example, they can be used to manufacture medicines or used as medicines.

Claims

1. A recombinant polypeptide capable of presenting a peptide antigen, the recombinant polypeptide comprising, in order from N-terminus to C-terminus: i) a peptide antigen presented by the recombinant polypeptide, wherein the peptide antigen is human proinsulin or a peptide of human insulin, human glutamic acid decarboxylase 65, human amylin or human zinc transporter 8; ii) optionally, a linker sequence; iii) optionally, a human polypeptide domain sequence, the human polypeptide domain sequence comprising a human β2 microglobulin sequence, or an amino acid sequence that is at least 90% identical to the human β2 microglobulin amino acid sequence shown in SEQ ID NO: 5; iv) optionally, a linker sequence; v) optionally, an α1 domain of an MHC molecule; vi) optionally, an α2 domain of an MHC molecule; vii) an α3 domain of an MHC class Ib molecule or a derivative of the α3 domain of an MHC class Ib molecule, said derivative being capable of binding to ILT2 or ILT4; viii) optionally, a protease cleavage site; ix) optionally, a spacer sequence; and x) Optionally, an affinity tag.

2. The recombinant polypeptide according to claim 1, wherein the peptide antigen according to i) has a length of 7 to 11 amino acids, preferably a length of 8 to 10 amino acids.

3. The recombinant polypeptide according to claim 1 or 2, wherein the peptide antigen according to i) consists of an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26 and SEQ ID NO:

27.

4. The recombinant polypeptide according to any one of the above claims, wherein the peptide antigen consists of an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 22 and SEQ ID NO:

23.

5. The recombinant polypeptide according to any one of claims 1 to 3, wherein the peptide antigen is a peptide antigen of human proinsulin or human insulin, and preferably consists of an amino acid sequence selected from the following group, the group consisting of the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO:

25.

6. The recombinant polypeptide according to any one of claims 1 to 3, wherein the peptide antigen is a peptide antigen of human glutamate decarboxylase 65, preferably consisting of an amino acid sequence selected from the following group, the group consisting of the amino acid sequences of SEQ ID NO: 23, SEQ ID NO: 26 and SEQ ID NO:

27.

7. The recombinant polypeptide according to any one of claims 1 to 3, wherein the peptide antigen is a peptide antigen of human glutamate decarboxylase 65, consisting of the amino acid sequence of SEQ ID NO:

26.

8. The recombinant polypeptide according to any one of claims 1 to 3, wherein the peptide antigen is a peptide antigen of human zinc transporter 8, and preferably consists of an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO: 22 and SEQ ID NO:

24.

9. The recombinant polypeptide according to any one of claims 1 to 3, wherein the peptide antigen is a peptide antigen of human amylin.

10. The recombinant polypeptide according to any one of the preceding claims, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from a human MHC class Ia molecule or from a human MHC class Ib molecule. 11 . The recombinant polypeptide according to claim 10 , wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human MHC class Ia molecules. 12 . The recombinant polypeptide according to claim 11 , wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human HLA-A2 molecules.

13. The recombinant polypeptide according to claim 10, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human MHC class Ib molecules. 14 . The recombinant polypeptide according to claim 13 , wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human HLA-G molecules.

15. The recombinant polypeptide according to any one of the preceding claims, wherein the α3 domain of the MHC class Ib molecule according to (vii) is the α3 domain of human HLA-E, human HLA-F or human HLA-G.

16. The recombinant polypeptide according to any one of the preceding claims, wherein the α3 domain of the MHC class Ib molecule according to (vii) is the α3 domain of human HLA-G.

17. A recombinant polypeptide according to any of the above claims, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence SEQ ID NO:9 or SEQ ID NO:21, or has at least 80% amino acid sequence identity, preferably at least 90% amino acid sequence identity, with the α3 domain having the amino acid sequence SEQ ID NO:9 or SEQ ID NO:

21.

18. A recombinant polypeptide according to claim 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 92% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

19. A recombinant polypeptide according to claim 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 94% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

20. The recombinant polypeptide according to claim 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 96% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

21. A recombinant polypeptide according to claim 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 98% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

22. A recombinant polypeptide according to claim 17, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 99% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

23. The recombinant polypeptide according to claim 17, wherein the α3 domain according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

24. A recombinant polypeptide according to any one of the preceding claims, wherein the linker sequence according to (ii) and / or the linker sequence according to (iv) comprises the amino acid sequence (GGGGS)n, wherein n is an integer equal to or greater than 1.

25. The recombinant polypeptide according to claim 24, wherein the linker sequence according to (ii) comprises the amino acid sequence (GGGGS)n, wherein n is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and is preferably selected from the group consisting of 2, 3, 4 and 5.

26. A recombinant polypeptide according to claim 24 or 25, wherein the linker sequence according to (iv) comprises the amino acid sequence (GGGGS)n, wherein n is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and is preferably selected from the group consisting of 2, 3, 4 and 5.

27. A recombinant polypeptide according to any one of the preceding claims, wherein the sequence of the human polypeptide domain according to (iii) is at least 95% identical to the amino acid sequence of SEQ ID NO:5, preferably at least 98% identical to the amino acid sequence of SEQ ID NO:5, and more preferably identical to the amino acid sequence of SEQ ID NO:

5.

28. The recombinant polypeptide according to any one of the above claims, wherein the polypeptide is a dimer or a multimer.

29. The recombinant polypeptide according to any one of the preceding claims, wherein the polypeptide comprises or consists of all components i) to vii).

30. The recombinant polypeptide according to any one of the preceding claims, wherein the polypeptide does not comprise components viii) to x).

31. The recombinant polypeptide according to any one of claims 1 to 29, wherein the polypeptide comprises or consists of all components i) to x).

32. The recombinant polypeptide according to any one of the above claims, further comprising an N-terminal secretion signal peptide sequence.

33. The recombinant polypeptide according to any one of claims 1 to 31, wherein the recombinant polypeptide consists of the following amino acid sequence, which consists of the following ((a) and (b)) in order from N-terminus to C-terminus: (a) a peptide antigen selected from the group consisting of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:2, and (b) The amino acid sequence of SEQ ID NO:

16.

34. The recombinant polypeptide according to any one of the above claims, wherein the recombinant polypeptide is soluble.

35. A nucleic acid encoding one or more polypeptides according to any one of the preceding claims.

36. The nucleic acid of claim 35, wherein the nucleic acid is a vector.

37. A pharmaceutical composition comprising at least one nucleic acid according to claim 35 or 36.

38. A pharmaceutical composition or kit comprising at least one recombinant polypeptide according to any one of claims 1-34.

39. The pharmaceutical composition or kit according to claim 38, wherein the pharmaceutical composition or kit comprises at least two different recombinant polypeptides according to any one of claims 1 to 34, and wherein each different polypeptide comprises a different peptide antigen as defined in any one of claims 3 to 9.

40. A pharmaceutical composition or kit according to claim 38 or 39, wherein the pharmaceutical composition or kit comprises at least the following ((A) to (C)): (A) a recombinant polypeptide, wherein the peptide antigen is a peptide antigen of human proinsulin or human insulin; (B) a recombinant polypeptide, wherein the peptide antigen is a peptide antigen of human glutamate decarboxylase 65; (C) a recombinant polypeptide, wherein the peptide antigen is a peptide antigen of human zinc transporter 8; and optionally further comprises (D) a recombinant polypeptide, wherein the peptide antigen is a peptide antigen of human amylin.

41. A pharmaceutical composition or kit according to any one of claims 38 to 40, wherein the pharmaceutical composition or kit comprises at least three different recombinant polypeptides according to any one of claims 1 to 34, wherein the peptide antigen of a first recombinant polypeptide among the at least three different recombinant polypeptides consists of the amino acid sequence of SEQ ID NO: 2, wherein the peptide antigen of a second recombinant polypeptide among the at least three different recombinant polypeptides consists of the amino acid sequence of SEQ ID NO: 22, and wherein the peptide antigen of a third recombinant polypeptide among the at least three different recombinant polypeptides consists of the amino acid sequence of SEQ ID NO:

23.

42. Use of a pharmaceutical composition or kit according to any one of claims 37-41 for treating type 1 diabetes in a human patient.

43. A pharmaceutical composition or kit for use according to claim 42, wherein the treatment is treatment by immunotherapy.

44. A pharmaceutical composition or kit for use according to any one of claims 42-43, wherein the treatment is performed by inducing immune tolerance to human proinsulin and / or human insulin, human glutamic acid decarboxylase 65, human amylin and / or human zinc transporter 8.

45. A pharmaceutical composition or kit for use according to any one of claims 42-44, wherein the treatment is used to reduce the level of insulin autoantibodies, i.e. insulin autoantibodies IAA, or glutamic acid decarboxylase (GAD-65), or islet antigen-2A (IA-2A), or zinc transporter ZnT8 in plasma, assessed by a radioactive binding assay or a non-radioactive electrochemiluminescent antigen binding assay.

46. ​​A pharmaceutical composition or kit for use according to any one of claims 42 to 45, wherein the human patient is a patient who has anti-insulin autoantibodies (insulin autoantibodies IAA), or glutamic acid decarboxylase (GAD-65), or islet antigen-2A (IA-2A), or zinc transporter ZnT8 in plasma before the start of treatment.

47. A recombinant host cell comprising the nucleic acid or vector according to claim 35 or 36, and expressing the recombinant polypeptide according to any one of claims 1-34.

48. A method for obtaining a pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 34, the method comprising the following steps: (a) culturing the recombinant host cell of claim 47 under conditions that allow expression of the recombinant polypeptide from the nucleic acid molecule, (a) recovering the recombinant polypeptide, (c) purifying the recombinant polypeptide, and (d) formulating the recombinant polypeptide into a pharmaceutical composition.